Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.66 |
| ▸ | NPC1 | O15118 | 6/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.66 |
| ▸ | TSHR | P16473 | 4/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31261554 | 0.90 | RAB9A (0.66) | RAB9ASMN1; SMN2TDP1NPC1MAPK1 | |
| SCHEMBL31261572 | 0.77 | LMNA (0.52) | RAB9ASMN1; SMN2TDP1NPC1MAPK1 | |
| SCHEMBL30935486 | 0.76 | SCN5A (0.44) | RAB9ASMN1; SMN2TDP1NPC1MAPK1 | |
| SCHEMBL14327884 | 0.76 | S1PR1 (0.70) | RAB9ASMN1; SMN2TDP1NPC1MAPK1 | |
| SCHEMBL26005529 | 0.76 | L3MBTL1 (0.70) | RAB9ASMN1; SMN2TDP1NPC1MAPK1 | |
| SCHEMBL31013417 | 0.75 | L3MBTL1 (0.61) | RAB9ANPC1TSHRL3MBTL1S1PR1 | |
| SCHEMBL3250198 | 0.75 | L3MBTL1 (0.61) | RAB9ANPC1TSHRL3MBTL1S1PR1 | |
| SCHEMBL19131277 | 0.75 | NPC1 (0.60) | RAB9ASMN1; SMN2TDP1NPC1MAPK1 | |
| SCHEMBL14741559 | 0.74 | TP53 (0.50) | RAB9ASMN1; SMN2NPC1MAPK1TSHR | |
| SCHEMBL14741772 | 0.74 | TP53 (0.44) | RAB9ASMN1; SMN2TDP1NPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630424-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | Third Harmonic Bio, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20240254119-A1 | COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS | Calixis Inc. | 2024-08-01 | — | — | US | disclosed |
| WO-2024124002-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254119-A1 | COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS | KIT, AURKC, PRKCE | RAB9A 1260/4885SMN1; SMN2 4236/4885TDP1 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.